Form 4: Disc Medicine Director, Mona Ashiya, Reports Stock Option Grant

Mona Ashiya, a director of Disc Medicine, Inc., reported the acquisition of stock options for 10,000 shares on June 12, 2024.

Summary

• On June 12, 2024, Mona Ashiya, a director of Disc Medicine, Inc. (IRON), was granted stock options to purchase 10,000 shares of common stock at an exercise price of $38.85.
• The options vest upon the earlier of the company's 2025 annual meeting or one year from the grant date, contingent on continued service.
• Ashiya is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will then provide them to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding stock option grants, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions, specifically the granting of stock options to a director. Such grants are common in the biotechnology industry as a form of compensation and incentive.

Related Party Transactions

• The Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing the company's value.

Key Dates